Blood Glucose Monitoring System Market: as pediatric clearance extends continuous monitoring to the one population that could never legally use it before, every age-band expansion now converts a caregiver-only wellness tool into a household medical device, so system-level design, not sensor accuracy alone, is becoming the basis for regulatory differentiation, and competitive advantage is moving toward companies that can clear the broadest age range fastest.

The global blood glucose monitoring system market size was USD 18.42 Billion in 2025 and is expected to register a revenue CAGR of 9.1% during the forecast period. Market revenue growth is driven by factors such as pediatric regulatory expansion of over-the-counter CGM systems, CMS reimbursement broadening for continuous monitoring, and integration between CGM and automated insulin delivery systems. The first driving factor is regulatory expansion of OTC CGM systems into pediatric use. Continuous glucose monitors account for approximately 62% of total 2025 market revenue, and until recently every OTC CGM clearance was confined to adults. The second driving factor is CMS and payer reimbursement broadening for continuous monitoring across a wider patient population. The third driving factor is deepening integration between CGM sensors and automated insulin delivery systems, which increases the clinical value of any single sensor by connecting it to a broader treatment ecosystem. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single CGM sensor platform accumulates compatibility with additional automated insulin delivery systems over time, which converts one sensor design into a widening set of integrated system sales without a new sensor architecture. Once a sensor platform earns compatibility with one insulin pump ecosystem, each additional pump-maker integration adds a new bundled system sale to the same underlying sensor hardware, so revenue per sensor design compounds as its compatibility list widens across the automated insulin delivery landscape. As a result, demand and revenue share are concentrating around sensor platforms with the broadest pump compatibility, and the forecast tilts toward integrated CGM-AID systems rather than standalone sensors sold without pump integration. For instance, in January 2026, Medtronic received FDA clearance for its MiniMed Go Smart Multiple Daily Injection system, integrating the InPen smart insulin pen with an Abbott-made sensor through a single connected app, one of a widening set of cross-company system integrations that let a single sensor platform reach patients across multiple insulin delivery ecosystems. These are some of the key factors driving revenue growth of the market.

Because CGM systems carry an ongoing monthly sensor cost well above traditional test strips, price-sensitive patients and healthcare systems in lower-income markets continue to rely on strip-based self-monitoring even as clinical guidelines increasingly favour continuous monitoring.

System integration complexity is a second constraint, because a CGM sensor's clinical value depends partly on its compatibility with a patient's specific insulin delivery system, so patients using an insulin pump not yet integrated with their preferred sensor face a real switching cost that slows adoption of otherwise superior sensor technology.

Pediatric adoption barriers are a third constraint, since pediatric CGM use requires caregiver supervision and shorter expected wear times than adult use, so pediatric-specific clearances, while regulatorily significant, convert to revenue more slowly than equivalent adult indications.

These factors substantially limit blood glucose monitoring system market growth over the forecast period.

The clearest driver of demand is FDA expansion of over-the-counter CGM clearance from adults-only to children as young as two years old. An adults-only clearance works as a hard population limit regardless of clinical need, so extending that clearance to children does not just add incremental volume, it opens an entirely new household user category that a family CGM purchase decision previously could not include. In June 2026, Dexcom received FDA clearance expanding its Stelo Glucose Biosensor System to children two years of age and older who do not use insulin, becoming the first OTC CGM available to a pediatric population. The FDA noted this clearance as an example of using real-world evidence to support regulatory decision-making, combining prior pediatric and adult clinical study data with real-world evidence rather than requiring a dedicated new pediatric trial. The effect on the market is that CGM system sales can now target household and family purchasing decisions rather than being confined to an individual adult user. These are some of the key factors driving revenue growth of the market.

The second driver is the deepening integration between CGM sensors made by one company and insulin delivery systems made by another. A standalone sensor's clinical value is capped by what a single company's own software and hardware can do with its data, so partnering a sensor with a separate company's insulin delivery or dosing-guidance software multiplies the sensor's addressable use cases without requiring the sensor manufacturer to build that downstream capability itself. In November 2025, Medtronic received FDA clearance for its SmartGuard algorithm as an interoperable automated glycemic controller compatible with the Abbott-made Instinct sensor, and in January 2026, Medtronic extended that partnership with FDA clearance for its MiniMed Go Smart Multiple Daily Injection system integrating the same sensor with its InPen smart insulin pen. The effect on the market is that sensor value is increasingly determined by the breadth of its downstream system integrations rather than by sensor accuracy alone. These are some of the key factors driving revenue growth of the market.

Dexcom's June 2026 pediatric clearance made Stelo the first over-the-counter CGM available to children as young as two. A device category built entirely around adult self-management just opened its first household user base.

The third driver is the emergence of dual-analyte sensors that measure a second physiological signal, such as ketones, alongside glucose on the same wearable platform. A single-analyte glucose sensor cannot detect diabetic ketoacidosis risk on its own, so adding ketone sensing to the same sensor form factor lets a system address a distinct and potentially life-threatening complication without requiring the patient to wear or purchase a second device. Abbott received a CE Mark in 2026 for its Libre Duo dual-analyte sensor, which continuously measures both glucose and ketone levels on the FreeStyle Libre 3 platform, with the company working alongside insulin pump makers including Tandem, Sequel Med Tech, and Beta Bionics to integrate the sensor with automated insulin delivery systems. The effect on the market is that system-level differentiation is expanding beyond glucose measurement accuracy into the number of clinically relevant signals a single wearable platform can track. These are some of the key factors driving revenue growth of the market.

However, the blood glucose monitoring system market faces severe adoption constraints from legacy BGM strip revenue erosion and high sensor costs in price-sensitive populations.

Because CGM systems carry an ongoing monthly sensor cost well above traditional test strips, price-sensitive patients and healthcare systems in lower-income markets continue to rely on strip-based self-monitoring even as clinical guidelines increasingly favour continuous monitoring, so legacy BGM revenue erodes unevenly across regions rather than uniformly.

System integration complexity compounds this, because a CGM sensor's clinical value depends partly on its compatibility with a patient's specific insulin delivery system, so patients using an insulin pump not yet integrated with their preferred sensor face a real switching cost that slows adoption of otherwise superior sensor technology.

Pediatric adoption barriers are the third constraint, since pediatric CGM use requires caregiver supervision and typically shorter wear times than adult use, so newly cleared pediatric indications, while regulatorily significant, convert to revenue more slowly than equivalent adult indications.

These factors substantially limit blood glucose monitoring system market growth over the forecast period.

Based on product type, the global blood glucose monitoring system market is segmented into continuous glucose monitors, self-monitoring blood glucose meters, test strips and lancets, and integrated CGM-AID systems. Continuous glucose monitors hold the largest revenue share, because pediatric and OTC regulatory expansion have widened the eligible user base faster than any other product category, which suits a market where regulatory access increasingly determines revenue potential. Self-monitoring blood glucose meters and test strips remain established in reimbursement-constrained markets and are cheaper per test than any CGM subscription, but they cannot deliver the continuous trend data that both clinicians and increasingly regulators now expect. Integrated CGM-AID systems are expected to register the fastest revenue growth rate in the global blood glucose monitoring system market over the forecast period, driven by Medtronic's cross-company sensor integrations, which is why other insulin delivery makers are pursuing similar third-party sensor partnerships.

Based on technology, the global blood glucose monitoring system market is segmented into wearable CGM biosensors, electrochemical strip-based BGM, and implantable long-duration CGM. Wearable CGM biosensors hold the largest revenue share, because they combine the continuous data clinicians want with a form factor that does not require an implantation procedure, which suits a market where ease of adoption matters as much as sensor longevity. Implantable long-duration CGM is expected to register the fastest revenue growth rate in the global blood glucose monitoring system market over the forecast period, driven by patient demand for reduced sensor-change frequency, which is why Senseonics' year-long Eversense 365 platform continues to expand its prescribing base among patients seeking the lowest-maintenance option.

Type 2 diabetes management application is expected to account for the largest revenue share in the global blood glucose monitoring system market during the forecast period

Based on application, the global blood glucose monitoring system market is segmented into type 1 diabetes management, type 2 diabetes management, and wellness and metabolic health monitoring. Type 2 diabetes management holds the largest revenue share, because the type 2 population is substantially larger than the type 1 population and OTC CGM clearance has specifically targeted non-insulin type 2 patients, which ties directly back to the regulatory expansion described in the market's primary demand driver. Wellness and metabolic health monitoring is expected to register the fastest revenue growth rate in the global blood glucose monitoring system market over the forecast period, driven by consumer interest in metabolic insight independent of a diabetes diagnosis, which is why Abbott's Lingo and Dexcom's Stelo are both marketed with wellness positioning alongside their clinical indications.

Based on regional analysis, the blood glucose monitoring system market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of FDA pediatric and system-integration clearances creates a direct consumer and clinical access pathway, and because Abbott, Dexcom, and Medtronic all maintain their primary commercial and regulatory presence in the US market. The breadth of automated insulin delivery pump makers based in the United States, including Tandem, Insulet, and Beta Bionics, anchors a domestic system-integration ecosystem large enough to sustain multiple competing sensor platforms simultaneously. The concentration of FDA clearance activity in the country also means new system-level integrations are typically launched in the United States first, before expanding to other regulatory jurisdictions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. Abbott secured its CE Mark for the Libre Duo dual-analyte sensor in Europe as its first regulatory jurisdiction, illustrating how European market entry can precede rather than follow US regulatory clearance for next-generation sensor technology. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent the two largest national markets within the region, driven by rising diabetes prevalence and expanding domestic manufacturing capacity. Japan is the earlier-launch market for advanced CGM systems in the region, which leaves more room for growth than in the already system-integration-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private payer networks driving early CGM system adoption among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the semiconductor and precision sensor components that Latin American device distributors depend on, an effect expected to run through 2026 and slow CGM system adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional distribution hubs represent the primary investment centres for glucose monitoring system adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the reimbursement and distribution infrastructure needed to support integrated CGM-AID systems at scale.